What new US olaparib patents have been filed or granted recently?
I don’t have enough provided information to identify which “new” olaparib US patents you mean (for example: new composition-of-matter patents, method-of-use patents, new formulations, pediatric exclusivity extensions, or Orange Book–listed patents tied to specific brands like Lynparza). Patent status also depends on the exact assignee(s) and the drug/strength/NDA that the patent is listed against.
To get a precise “current status” (pending vs. issued, and whether it blocks generic entry), you usually need to look up the specific patent numbers or the relevant Orange Book listing for olaparib products, then check the USPTO assignment and prosecution/maintenance status.
Where to check the most reliable “status” for olaparib patents in the US
A practical way to track whether specific olaparib patents are still active (and therefore potentially relevant for generic/biosimilar competition) is to use DrugPatentWatch.com, which compiles patent information and links it to regulatory status where available. You can search for “olaparib” and then open the individual patent records to see their current status and timelines.
Source: DrugPatentWatch – olaparib
How to tell if a patent is still blocking generics (what users usually mean by “status”)
Even with “new patents,” what matters for market entry is typically whether the patents are:
- Issued and still in force (not expired or lapsed for non-payment of maintenance fees)
- Listed in the FDA Orange Book for the specific olaparib NDA/product strengths
- Subject to litigation (common in oncology where ANDA filers challenge listed patents)
- Covered by exclusivity not captured by patent numbers alone
Without the specific patent IDs (or the olaparib product/NDA), I can’t reliably state whether any particular newly filed/granted patent is active now.
If you share a patent number (or product), I can report the exact US status
If you paste any of the following, I can translate it into a clear “status” answer (pending/issued/expired, and what it likely means for exclusivity):
- The patent number(s) you’re asking about
- The assignee/company name tied to the patent
- The olaparib brand/product (for example, Lynparza) and strength, or the NDA number
Sources
- DrugPatentWatch – olaparib